Merck’s 9-Valent HPV Vaccine, GARDASIL®9, Recommended by CDC’s Advisory Committee on Immunization Practices for Females Aged 9-26 and Males Aged 9-21
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that the U.S. Centers for Disease Control and
Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP)
voted to include GARDASIL®9 (Human Papillomavirus 9-valent
Vaccine, Recombinant) in the recommendations for use of HPV vaccines.
GARDASIL 9 has been added to the routine recommendations for vaccination
of 11- and 12- year-old females and males. The vacci...
Source: Merck.com - Corporate News - February 26, 2015 Category: Pharmaceuticals Tags: Vaccine News Corporate News Latest News Source Type: news
Merck Announces Second-Quarter 2015 Dividend
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Board of Directors has declared a quarterly
dividend of $0.45 per share of the company’s common stock for the second
quarter of 2015. Payment will be made on Apr. 8, 2015, to stockholders
of record at the close of business on Mar. 16, 2015.
About Merck
Language:
English
Contact:
...
Source: Merck.com - Corporate News - February 24, 2015 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
Merck, on Behalf of Its Wholly Owned Subsidiary Cubist Pharmaceuticals, Announces Results of Tender Offer for Cubist’s 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes Due 2018 and 1.875% Convertible Senior Notes Due 2020
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, on
behalf of its wholly owned subsidiary Cubist Pharmaceuticals, Inc.,
today announced the results of its tender offer (the “Convertible
Notes Tender Offer”) pursuant to which each holder of Cubist’s
2.50% Convertible Senior Notes due 2017 (the “2017
Convertible Notes”), 1.125% Convertible Senior Notes due 2018
(the “2018 Convertible Notes”) and 1.875%
Convertible Senior ...
Source: Merck.com - Corporate News - February 23, 2015 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics
Dateline City:
SOUTH SAN FRANCISCO, Calif. & KENILWORTH, N.J.
Partnership Combines NGM’s Unique Biology-focused Research Platform with Merck’s Late-stage Clinical and Commercialization Strengths to Discover Medicines for Serious Diseases
SOUTH SAN FRANCISCO, Calif. & KENILWORTH, N.J.--(BUSINESS WIRE)--
NGM Biopharmaceuticals, Inc., a privately-held biotechnology company and
Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the...
Source: Merck.com - Corporate News - February 23, 2015 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck Prices $8.0 Billion Debt Offering
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (the “Company”) (NYSE:MRK), known as MSD outside of
the United States and Canada, priced today an $8.0 billion public
offering of senior unsecured notes (collectively, the “Notes”). The
Notes include:
$300 million of floating rate notes due February 2017
$700 million of floating rate notes due February 2020
$1,250 million of 1.850% notes due February 2020
$1,250 million of 2.350% notes due Fe...
Source: Merck.com - Corporate News - February 6, 2015 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
Merck Announces Fourth-Quarter and Full-Year 2014 Financial Results
Dateline City:
KENILWORTH, N.J.
Fourth-Quarter 2014 Non-GAAP EPS of $0.87, Excluding Certain Items; GAAP EPS of $2.54; Full-Year 2014 Non-GAAP EPS of $3.49, Excluding Certain Items; GAAP EPS of $4.07
2015 Full-Year Non-GAAP EPS Target of $3.32 to $3.47, Including a $0.27 Negative Impact From Foreign Exchange and Excluding Certain Items; GAAP EPS Range of $1.62 to $1.91
Fourth-Quarter 2014 Worldwide Sales of $10.5 Billion, a Decrease of 7 Perce...
Source: Merck.com - Corporate News - February 4, 2015 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
Merck’s Insomnia Medicine BELSOMRA® (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that BELSOMRA® (suvorexant) is now available
at pharmacies in the United States for the treatment of insomnia in
adults who have difficulty falling asleep and/or staying asleep.
BELSOMRA is the only orexin receptor antagonist approved for the
treatment of insomnia in the United States. Orexin is one of the many
neurotransmitters in the brain involved in promoting wakefulness,...
Source: Merck.com - Corporate News - February 3, 2015 Category: Pharmaceuticals Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Merck, on Behalf of its Wholly Owned Subsidiary, Cubist Pharmaceuticals, Announces Tender Offer for Cubist’s 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes due 2018 and 1.875% Convertible Senior Notes due 2020
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, on
behalf of its wholly owned subsidiary Cubist Pharmaceuticals, Inc.,
today announced that, in connection with the completion of the
acquisition of Cubist by Merck, Cubist has commenced a tender offer (the
“Convertible Notes Tender Offer”) to
repurchase, at the option of each holder, any and all of its outstanding
2.50% Convertible Senior Notes due 2017 (the “2017
Convertible No...
Source: Merck.com - Corporate News - January 22, 2015 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
Merck Completes Tender Offer to Acquire Cubist
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced the successful completion of the tender offer for all of the
outstanding shares of common stock of Cubist Pharmaceuticals, Inc.
(NASDAQ: CBST) at a purchase price of $102.00 per share.
Language:
English
Contact:
MerckMedia:Lainie Keller, 908-236-5036orSteve Cragl...
Source: Merck.com - Corporate News - January 21, 2015 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
Merck Provides Update on Strategic Actions to Transform the Company and Build a Platform for Sustained Future Growth at the 33rd Annual J.P. Morgan Healthcare Conference
Dateline City:
KENILWORTH, N.J.
KEYTRUDA, First FDA-Approved Anti-PD-1 Therapy, Filed and Launched Within Five Months
Company Expects to Submit sBLA for KEYTRUDA in Mid-Year 2015 for Advanced Non-Small Cell Lung Cancer
NDA Submission for Hepatitis C Combination Regimen, Grazoprevir/Elbasvir (MK-5172/MK-8742), Planned for First Half of 2015
Seven New Products were Approved in 2014
Company Announced Acquisition of Cubist, Acquired ...
Source: Merck.com - Corporate News - January 12, 2015 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that Kenneth C. Frazier, Merck’s chairman and chief
executive officer, is scheduled to present at the 33rd Annual
J.P. Morgan Healthcare Conference in San Francisco on Jan. 12, 2015 at
4:00 p.m. PST (7:00 p.m. EST). Investors, analysts, members of the media
and the general public are invited to listen to a live audio webcast of
the presentation at http://www.merck.com/inves...
Source: Merck.com - Corporate News - January 9, 2015 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck to Hold Fourth-Quarter and Full-Year 2014 Sales and Earnings Conference Call on February 4
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
will hold its fourth-quarter and full-year 2014 sales and earnings
conference call with institutional investors and analysts at 8:00 a.m.
EST on Wednesday, Feb. 4. During the call, company executives will
provide an overview of Merck’s performance for the quarter and full year.
Language:
English
Contact:
...
Source: Merck.com - Corporate News - January 5, 2015 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
Merck Begins Tender Offer to Acquire Cubist
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, is
commencing today, through a subsidiary, a cash tender to purchase all
outstanding shares of common stock of Cubist Pharmaceuticals, Inc.
(NASDAQ:CBST). On Dec. 8, 2014, Merck announced its intent to acquire
Cubist.
Language:
English
Contact:
MerckMedia:Lainie Keller...
Source: Merck.com - Corporate News - December 19, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers
Dateline City:
KENILWORTH, N.J.
Acquisition Expands Merck’s Oncology Portfolio with Novel Oral BET Inhibitor, OTX015
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that it has acquired, through a subsidiary, OncoEthix, a
Swiss-based privately held biotechnology company specializing in
oncology drug development. Through the acquisition, Merck has gained an
investigational, novel oral BET (br...
Source: Merck.com - Corporate News - December 18, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck Announces Appointment of Dr. Julie Gerberding as Executive Vice President for Strategic Communications, Global Public Policy and Population Health
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the appointment of Dr. Julie Gerberding, 59, as
executive vice president for strategic communications, global public
policy and population health, effective Dec. 15.
Language:
English
Contact:
MerckMedia:Steven Cragle, 908-740-1801Lainie Keller, 908-236-5036...
Source: Merck.com - Corporate News - December 10, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
